Divis Laboratories Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/so2lhwwl8l3cuu8nzvmnw0v6.pdf

Key Takeaways


Custom Synthesis: The Next Growth Engine

Dr. Kiran S. Divi: "Pricing is one factor. Capacity is one factor. Divi's always is one step ahead in terms of capacity in terms of looking at forward, thinking in terms of creating capacity. But that is not the only thing. There are several factors you have to look at, unless you tick all the boxes, any multinational would not work with any firm."

Peptide Synthesis: The Focused Bet

Dr. Kiran S. Divi: "Divi has strategically decided that we will not look at generic part of peptide synthesis. We are right now fully occupied with the amount of CS projects we have. So, we do not want to venture into that mode."

Generic Business: Volume Resilience, Price Pain


Margins: Stable but Constrained


Capex & Capacity: Building Ahead of Demand

Dr. Kiran S. Divi: "See, for us, nothing happens overnight. It's pretty strategically planned taken decisions which are thought through and where our strengths match. It's not like, okay, today, there's an opportunity, so let's jump on the bandwagon and go."

Contrast Media & Other Platforms


Guidance & Commitments

CommitmentSpecificsTimeline
Constant-currency revenue growthAround 10.79% for the full year, consistent with H1 run-rateFY26
Custom synthesis commercial manufacturingA few projects in development/validation to enter commercial manufacturingNext 1 to 2 years
Three disclosed CS projects revenueRevenue to begin, provided all regulatory approvals are in place with no agency hurdlesNext 1 to 2 years
Generic pricing pressureNo improvement expectedAt least next 2 quarters
Unit 3 GMP qualificationSubmit Drug Master Files and obtain qualifications for in-house APIsNext few quarters
Asset turnoverPositive outlook given new opportunitiesNext 1 to 2 years
Gadolinium product revenueRegulatory process across countries takes at least 1 year post-approval before any revenueAt least 1 year post-approval

Key Metrics

MetricQ2 FY26
Consolidated total income₹2,860 cr, +17% YoY from ₹2,444 cr
Profit before tax₹912 cr, +26% YoY from ₹722 cr
Profit after tax₹689 cr, +35% YoY from ₹510 cr
Material consumption39.5% of sales revenue, consistent with recent trend
Forex gain₹63 cr
Constant currency revenue growth10.79% YoY
Exports share90% of total sales revenue
Europe and US export share74% combined of total sales revenue
Product mix (Generics / Custom Synthesis)44% / 56%
Nutraceutical revenue₹242 cr
H1 FY26 consolidated total income₹5,389 cr, +16% YoY from ₹4,640 cr
H1 FY26 profit before tax₹1,645 cr, +24% YoY from ₹1,326 cr
H1 FY26 material consumption39.6% of sales revenue, improved from 40.9% in H1 FY25
H1 FY26 capex spend~₹1,550 cr, against FY26 guidance of ~₹2,000 cr
Generic business revenue growth (last 4 quarters)~7% (per an analyst's math)